Wegovy vs Zepbound
Wegovy and Zepbound are the two FDA-approved weight-management brands of the GLP-1 class. Wegovy is semaglutide; Zepbound is tirzepatide. The molecule-level comparison is the same comparison as semaglutide vs tirzepatide — Wegovy is GLP-1 mono-agonism, Zepbound is dual GIP/GLP-1. Choice is provider-reviewed against biomarkers, tolerance, cardiovascular history, and access.
Choose Wegovy when the longer cardiovascular outcome track record matters, when access favors semaglutide, or when prior tolerance favors GLP-1 mono-agonism.
Choose Zepbound when the priority is the larger average weight-loss effect at maximum tolerated dose and candidacy and access support it.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Are Wegovy and Ozempic the same?
Same molecule (semaglutide), different FDA-approved indication. Wegovy is approved for chronic weight management; Ozempic is approved for type-2 diabetes. Dosing schedules differ.
Are Zepbound and Mounjaro the same?
Same molecule (tirzepatide), different FDA-approved indication. Zepbound is approved for chronic weight management; Mounjaro is approved for type-2 diabetes.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment